Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial

Authors

Institutions

Publication Details

Journal
EClinicalMedicine
Published
2025-05-01
DOI
https://doi.org/10.1016/j.eclinm.2025.103229
Citations
19
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
19.86

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial

Ke Sha, Heng Mei, Chunli Mei, Mei-Lin Ma et al.
19 citations
EClinicalMedicine
CAR-T cell therapy research
19.86
article

Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial

Ke Sha, Heng Mei, Chunli Mei, Mei-Lin Ma, Yu Hu, Wei Xie, Anqi Ren, Jinhui Shu, Zisong Zhou
article en
19 citations

Abstract

No abstract available for this paper.
EClinicalMedicineVol. 83
Union Hospital (HK), Hubei Cancer Hospital (CN), Huazhong University of Science and Technology (CN)
National Natural Science Foundation of China, Key Technologies Research and Development Program, National Key Research and Development Program of China
Good health and well-being
Openalex Percentile: Top 1%
CAR-T cell therapy research
19.86
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.